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Introductory text 
Children with severe, undiagnosed developmental disorders (DDs) are enriched for 
damaging de novo mutations (DNMs) in developmentally important genes. We exome 
sequenced 4,294 families with children with DDs, and meta-analysed these data with 
published data on 3,287 children with similar disorders. We show that the most significant 
factors influencing the diagnostic yield of de novo mutations are the sex of the child, the 
relatedness of their parents and the age of both father and mother. We identified 95 genes 
enriched for damaging de novo mutation at genome-wide significance (P < 5 x 10-7), 
including fourteen genes for which compelling data for causation was previously lacking. 
The large number of genome-wide significant findings allow us to demonstrate that, at 
current cost differentials, exome sequencing has much greater power than genome 
sequencing for novel gene discovery in genetically heterogeneous disorders. We estimate 
that 42.5% of our cohort likely carry pathogenic de novo single nucleotide variants (SNVs) 
and indels in coding sequences, with approximately half operating by a loss-of-function 
mechanism, and the remainder being gain-of-function. We established that most 
haploinsufficient developmental disorders have already been identified, but that many gain-
of-function disorders remain to be discovered. Extrapolating from the DDD cohort to the 
general population, we estimate that de novo dominant developmental disorders have an 
average birth prevalence of 1 in 168 to 1 in 377, depending on parental age. 
 
Main text 
Within the Deciphering Developmental Disorders study1 we recruited 4,294 individuals with 
severe undiagnosed developmental disorders, most of which were the only affected family 
member. We sequenced the exomes of these individuals and their parents. Analyses of 
1,133 of these trios were described previously1. We generated a high sensitivity set of 8,361 
candidate DNMs in coding or splicing sequence (mean of 1.95 DNMs per proband), while 
removing systematic erroneous calls (Supplementary Table 1). 1,624 genes contained two or 
more DNMs in unrelated individuals. 
 
Figure 1 - factors influencing presence of pathogenic DNM 
 
Twenty-three percent of individuals had likely pathogenic protein-truncating or missense 
DNMs within a clinically curated set of genes robustly associated with developmental 
disorders (http://www.ebi.ac.uk/gene2phenotype). We investigated factors associated with 
whether an individual had a likely pathogenic DNM in these curated genes (Figure 1 A, B). 
We observed that males were less likely to carry a likely pathogenic DNM (P = 1.8 x 10-4; OR 
0.75, 0.65 - 0.87 95% CI), as has also been observed in autism2. We also observed increased 
likelihood of having a pathogenic DNM with the extent of speech delay (P = 0.00123), but 
not other indicators of severity. Furthermore, the total genomic extent of autozygosity (due 
to parental relatedness) was negatively correlated with the likelihood of having a 
pathogenic DNM (P = 1.4 x 10-5), for every log10 increase in autozygous length, the 
probability of having a pathogenic DNM dropped by 7.5%, likely due to increasing burden of 
recessive causation (Figure 1 C). Nonetheless, 6% of individuals with autozygosity equivalent 
to a first cousin union or greater had a likely pathogenic DNM, underscoring the important 
of considering de novo causation in all families.  
 
Paternal age has been shown to be the primary factor influencing the number of DNMs in a 
child3,4, and thus is expected to be a risk factor for pathogenic DNMs. While paternal age 
was only weakly associated with likelihood of having a pathogenic DNM (P = 0.016), focusing 
on the minority of DNMs that were truncating and missense variants in known DD-
associated genes limits our power to detect such an effect. Analysing all 8,409 high 
confidence exonic and intronic autosomal DNMs confirmed a strong paternal age effect (P = 
1.4 x 10-10, 1.53 DNMs/year, 1.07-2.01 95% CI), as well as highlighting a weaker, 
independent, maternal age effect (P = 0.0019, 0.86 DNMs/year, 0.32-1.40 95% CI, Figure 1 
D, E), as has recently been described in whole genome analyses5.  
 
Figure 2 – Manhattan plot 
Figure 3 – phenotypic summary of ‘previously not compelling’ genes 
Table 1 – summary of DNMs and p values in ‘previously not compelling’ genes 
 
We identified genes significantly enriched for damaging DNMs by comparing the observed 
gene-wise DNM count to that expected under a null mutation model6, as described 
previously1. We meta-analysed with 4,224 published DNMs in 3,287 affected individuals 
from thirteen exome or genome sequencing studies (Supplementary Table 3)7-18 that 
exhibited a similar excess of DNMs in our curated set of DD-associated genes 
(Supplementary Figure 1). We found 93 genes with genome-wide significance (P < 5 × 10-7), 
76 of which were in our curated gene set (Supplementary Table 4). Some disorders are 
considerably more clinically distinctive than others (Supplementary Figure 2). To increase 
power to detect novel DD-associated genes, we then excluded individuals with likely 
pathogenic variants in known DD-associated genes1, leaving 3,158 probands from our 
cohort, along with 2,955 probands from the meta-analysis studies (Supplementary Table 5). 
In this subset, we identified fourteen genome-wide significant genes for which compelling 
evidence for causation has not previously been presented: CDK13, CHD4, CNOT3, CSNK2A1, 
GNAI1, KCNQ3, MSL3, PPM1D, PUF60, QRICH1, SET, SUV420H1, TCF20, and ZBTB18 (P < 5 x 
10-7, Table 1, Supplementary Figure 3). The clinical features associated with these novel 
disorders are summarised in Figure 3. QRICH1 and SET would not achieve genome-wide 
significance without excluding individuals with likely pathogenic variants. We found USP9X 
and ZC4H4 had a genome-wide significant excess in female probands, indicating these genes 
have X-linked dominant modes of inheritance in addition to previously reported X-linked 
recessive mode of inheritance in males. In addition, we identified a novel seizure disorder 
caused by truncating mutations in SMC1A (P = 6.5 x 10-19), a DD-associated gene in which 
missense mutations cause a distinct disorder, Cornelia de Lange Syndrome. Only one PTV 
mutation in SMC1A had previously been reported19. 
 
We additionally exome sequenced 566 ‘case’ individuals with DDs for which parental DNA 
was not available, and 4,100 ‘control’ individuals without known neurodevelopmental 
phenotypes20. Cases exhibited an excess of rare PTVs in DD-associated dominant genes (P = 
2.7 x 10-22; OR 4.78, 4.07 - 5.63 95% CI). After excluding 90 cases with rare PTVs in dominant 
DD-associated genes, cases still had a modest exome-wide excess of rare PTVs (P = 4.3 x 10-
3; OR 1.07, 1.04 - 1.09 95% CI). Furthermore, we found a significant enrichment of rare PTVs 
in the fifteen novel developmental disorder genes (P = 1.5 x 10-5; OR = 11.7, 6.5 - 21.2 95% 
CI), providing additional evidence that disruptive variants in these newly associated genes 
confer risk for developmental disorders. 
 
 
The above analyses focus exclusively on the genetic evidence for association. We explored 
two alternative strategies for integrating phenotypic data: statistical assessment of 
phenotypic similarity between individuals sharing candidate DNMs in the same gene (as we 
described previously21) and phenotypic stratification. We found that while combining 
genetic evidence and phenotypic similarity increased the significance of some known DD-
associated genes considerably, significance decreased for a larger number of DD-associated 
gene that cause relatively indistinct disorders (Supplementary Figure 4 A). Therefore, we did 
not incorporate phenotypic similarity in the gene discovery analyses described above.  
 
We also investigated phenotypic stratification by comparing gene-wise analyses of the 20% 
of individuals who had experienced seizures, with gene-wise analyses of the entire cohort, 
to see if it increased power to detect known seizure-associated genes (Supplementary 
Figure 4 B). Fifteen seizure-associated genes were genome-wide significant within both the 
seizure-only and the entire-cohort analyses. Furthermore, nine seizure-associated genes 
were genome-wide significant in the entire cohort but not in the seizure subset. Of the 285 
individuals with truncating or missense DNMs in known seizure-associated genes, 56% of 
individuals had not experienced seizures. This observation is not likely to be due to the 
individuals manifesting seizures having more damaging DNMs as the proportions of 
truncating mutations were not significantly different between individuals with and without 
seizures (P = 0.05). These findings suggest that there is sufficient shared genetic etiology 
between individuals with seizures and individuals with other neurodevelopmental disorders 
in our cohort that increased sample size far outweighs greater phenotypic specificity. 
 
Figure 4 - power of exome and genome sequencing under different assumptions 
 
The large number of genome-wide significant genes identified in the analyses above allows 
us to compare empirically different experimental strategies for novel gene discovery in a 
genetically heterogeneous cohort such as ours. We compared the power of exome and 
genome sequencing to detect genome-wide significant genes, assuming that budget and not 
samples are limiting, under different scenarios of cost ratios and sensitivity ratios (Figure 4). 
We found that at current cost ratios (exome costs 30-40% of a genome) and with a plausible 
sensitivity differential (genome detects 5% more exonic variants than exome22) exome 
sequencing detects more than twice as many genome-wide significant genes. These 
empirical estimates were consistent with power simulations for identifying dominant loss-
of-function genes (Supplementary Figure 5). The close agreement of empirical estimates 
and power simulations based on germline mutation rates are consistent with few de novo 
mutations being lost due to prenatal lethality. In summary, while genome sequencing gives 
greatest sensitivity to detect pathogenic variation in a single individual, exome sequencing is 
more powerful for novel gene discovery (and, analogously, likely delivers lower cost per 
diagnosis). 
 
Figure 5 – DNM excess for recognisability and consequence, also by constraint quantile 
 
Our previous simulations suggested that analysis of a cohort of 4,294 DDD families ought to 
be able to detect approximately half of all haploinsufficient DD-associated genes at genome-
wide significance1. Empirically, we identified 47% (50/107) of haploinsufficient genes 
previously robustly associated with neurodevelopmental disorders. We hypothesised that 
genetic testing prior to recruitment into our study may have depleted the cohort of the 
most clinically recognisable disorders. Indeed, we observed that the genes associated with 
the most clinically recognisable disorders were associated with a significant, three-fold 
lower enrichment of truncating DNMs than other DD-associated genes (~40X enrichment vs 
~120X enrichment, Figure 5 A). Removing these most recognisable disorders from the 
analysis, we identified 55% (42/76) of the remaining haploinsufficient DD-associated genes. 
The known DD-associated haploinsufficient genes that did not reach genome-wide 
significance were clearly enriched for those with lower mutability, which we would expect 
to lower power to detect in our analyses. We identified DD-associated genes (e.g. NRXN2) 
with high mutability, low clinical recognisability and yet no signal of enrichment for DNMs in 
our cohort (Supplementary Figure 6). Our analyses call into question whether these genes 
really are associated with haploinsufficient neurodevelopmental disorders and highlights 
the potential for well-powered gene discovery analyses to refute prior credence regarding 
gene causation.  
 
We estimated the likely prevalence of pathogenic missense and truncating DNMs within our 
cohort by increasing the stringency of called DNMs until the observed synonymous DNMs 
equated to that expected under the null mutation model, and then quantifying the excess of 
observed missense and truncating DNMs (Figure 5 B). We observed an excess of 591 
truncating and 1,236 missense mutations, suggesting 42.5% of the cohort has a pathogenic 
DNM. The vast majority of synonymous DNMs are likely to be benign, as evidenced by them 
being distributed uniformly (Figure 5 C) among genes irrespective of their tolerance of 
truncating variation in the general population (as quantified by the probability of being LoF-
intolerant (pLI) metric23). By contrast, missense and truncating DNMs are significantly 
enriched in genes with the highest probabilities of being intolerant of truncating variation 
(Figure 5 C). Only 51% (923/1816) of these excess missense and truncating DNMs mutated 
DD-associated dominant genes, with the remainder likely to affect genes not yet associated 
with DDs. A much high proportion of the excess truncating DNMs (70%) than missense 
DNMs (42%) mutated known DD-associated genes, suggesting that whereas most 
haploinsufficient DD-associated genes have already been identified, there remain to be 
discovered many DD-associated genes characterised by pathogenic missense DNMs. 
 
We sought to estimate the relative proportion of gain-of-function and loss-of-function  
missense DNMs in our cohort, taking advantage of the different population genetic 
characteristics of known gain-of-function and loss-of-function DD-associated genes. 
Specifically, we observed that, as might be expected, these two classes of DD-associated 
genes are differentially depleted of truncating variation in the general population (pLI 
metric23). We modelled the observed pLI distribution of excess missense DNMs as a mixture 
of the pLI distributions of known gain-of-function and loss-of-function DD-associated genes 
(Figure 5 D, E), and estimated that 63% of excess missense DNMs are likely gain-of-function. 
If we assume that all truncating mutations are operating by a loss-of-function mechanism, 
then 57% of excess missense and truncating DNMs are loss-of-function and 43% are gain-of-
function. 
 
Figure 6-  Parental age vs birth prevalence, underplotted with parental age distributions 
 
We estimated the birth prevalence of dominant developmental disorders by using the 
germline mutation model to calculate the expected cumulative germline mutation rate of 
truncating DNMs in haploinsufficient DD-associated genes and scaling this upwards based 
on the composition of excess DNMs in the DDD cohort described above (see Methods), 
correcting for disorders that are under-represented in our cohort as a result of prior genetic 
testing (e.g. clinically-recognisable disorders and large pathogenic CNVs identified by 
chromosomal microarray analysis). This gives a mean prevalence estimate of 0.42%, or 1 in 
235 births. By factoring in the paternal and maternal age effects on the mutation rate 
(Figure 1) we modelled age-specific estimates of birth prevalence (Figure 6) that range from 
1 in 377 (both mother and father aged 20) to 1 in 168 (mother and father aged 45). 
 
In summary, we have shown that dominant mutations account for approximate half of the 
genetic architecture of severe developmental disorders, and are split roughly equally 
between loss-of-function and gain-of-function. Whereas most haploinsufficient DD-
associated genes have already been identified, currently many activating and dominant 
negative DD-associated genes have eluded discovery. This elusiveness likely results from 
these disorders being individually rarer, as a result of being caused by a relatively small 
number of missense mutations within each gene. We have assessed empirically different 
experimental and analytical strategies for identifying DD-associated genes. Discovery of the 
remaining dominant developmental disorders will be driven by larger studies and novel, 
more powerful, analytical strategies for disease-gene association that leverage gene-specific 
patterns of population variation, specifically the observed depletion of damaging variation. 
We have estimated the mean birth prevalence of dominant developmental disorders to be 1 
in 236, which is greater than the combined impact of the three aneuploidies (Down, 
Edwards, Patau)24 and highlights the cumulative population morbidity and mortality 
imposed by these disorders. 
 
 
  
Methods 
 
Being drafted. 
  
 Figures 
 
 
Figure 1: Association of phenotypes with presence of likely pathogenic de novo mutations. A) Odds 
ratios and 95% confidence intervals (CI) for binary phenotypes. Positive odds ratios are associated 
with increased risk of pathogenic de novo mutations when the phenotype is present. P-values are 
given for a Fisher’s Exact test. B) Beta coefficients and 95% CI from logistic regression of quantitative 
phenotypes versus presence of a pathogenic de novo mutation. All phenotypes aside from length of 
autozygous regions were corrected for gender as a covariate. The developmental milestones (age to 
achieve first words, walk independently, sit independently and social smile) were log-scaled before 
regression. The growth parameters (height, birthweight and OFC) were evaluated as absolute 
distance from the median. C) Relationship between length of autozygous regions chance of having a 
pathogenic de novo mutation. The regression line is plotted as the dark gray line. The 95% 
confidence interval for the regression is shaded gray. The autozygosity lengths expected under 
different degrees of consanguineous unions are shown as vertical dashed lines. n, number of 
probands in each autozygosity group. D) Relationship between age of fathers at probands birth and 
number of high confidence de novo mutations. n, number of high confidence de novo mutations. E) 
Relationship between age of mothers at probands birth and number of high confidence de novo 
mutations. n, number of high confidence de novo mutations.  
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Figure 2: Initial genes exceeding genome-wide significance. Manhattan plot of combined P-values 
across all tested genes. The red dashed line indicates the threshold for genome-wide significance (P 
< 5 x 10-7). Genes exceeding this threshold have HGNC symbols labelled. Composite facial images 
from individuals with DNMs in selected genes are included for the six most-significantly associated 
genes.  
  
  
Figure 3: Phenotypic summary of genes without previous compelling evidence. Phenotypes are 
grouped by type. The first group indicates counts of individuals with DNMs per gene by sex. The 
second group indicates mean values for growth parameters: birthweight (bw), height (ht), weight 
(wt), occipitofrontal circumference (ofc). Values are given as standard deviations from the healthy 
population mean. The third group indicates the mean age for achieving developmental milestones: 
age of first social smile, age of first sitting unassisted, age of first walking unassisted and age of first 
speaking. Values are given in months. The final group summarises Human Phenotype Ontology 
(HPO)-coded phenotypes per gene, as counts of HPO-terms within different clinical categories. 
  
  
Figure 4: Power of genome versus exome sequencing to discover novel genes. The regions where 
exome sequencing costs 30-40% of genome sequencing are shaded with a gray background, which 
corresponds to the price differential in 2015. 
  
  
Figure 5: Excess of de novo mutations (DNMs). A) Enrichment ratios of observed to expected loss-of-
function DNMs by clinical recognisability for dominant haploinsufficient neurodevelopmental genes. 
B) Enrichment of DNMs by consequence. C) Enrichment ratios of observed to expected DNMs by 
constraint quantile for loss-of-function, missense and synonymous DNMs. Counts of DNMs in each 
lower and upper half of the quantiles are provided. D) Normalised excess of observed to expected 
DNMs by constraint quantile. This includes missense DNMs within all genes, loss-of-function and 
missense DNMs in dominant haploinsufficient genes and missense DNMs in dominant 
nonhaploinsufficient genes (genes with dominant negative or activating mechanisms). E) Goodness-
of-fit for mixture models across the range of loss-of-function proportions. 
  
 Figure 6: Prevalence of live births with developmental disorders caused by dominant de novo 
mutations (DNMs). The prevalence within the general population is provided as percentage for 
combinations of parental ages, extrapolated from the maternal and paternal rates of DNMs. 
Distributions of parental ages within the DDD cohort and the UK population are shown at the 
matching parental axis. 
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Table 1: Genes achieving genome-wide significant statistical evidence without previous compelling 
evidence for being developmental disorder genes. The numbers of unrelated individuals with 
independent de novo mutations are given for protein truncating variants (PTV) and missense 
variants. If any additional individuals were in other cohorts, that number is given in brackets. The P-
value reported is the minimum P-value from the testing of the DDD dataset or the meta-analysis 
dataset. The subset providing the P-value is also listed. Mutations are considered clustered if the P-
value proximity clustering of de novo mutations is less than 0.01. 
Gene Missense PTV P-value Test Clustering 
CDK13 10 1 3.2 x 10-19 DDD Yes 
GNAI1 7 (1) 1 2.1 x 10-13 DDD No 
CSNK2A1 7 0 1.4 x 10-12 DDD Yes 
PPM1D 0 5 (1) 6.3 x 10-12 Meta No 
CNOT3 5 2 (1) 5.2 x 10-11 DDD Yes 
MSL3 0 4 2.2 x 10-10 DDD No 
KCNQ3 4 (3) 0 3.4 x 10-10 Meta Yes 
ZBTB18 1 (1) 4 1.4 x 10-9 DDD No 
PUF60 4 (1) 3 2.6 x 10-9 DDD No 
TCF20 1 5 2.7 x 10-9 DDD No 
SUV420H1 0 (2) 2 (3) 2.9 x 10-9 Meta No 
CHD4 8 (1) 1 7.6 x 10-9 DDD No 
SET 0 3 1.2 x 10-7 DDD No 
QRICH1 0 3 (1) 3.6 x 10-7 Meta No 
 
 
 
 
 
 
  
References 
1. The Deciphering Developmental Disorders Study. Large-scale discovery of novel 
genetic causes of developmental disorders. Nature 519, 223-228 (2015). 
2. Jacquemont, S. et al. A higher mutational burden in females supports a "female 
protective model" in neurodevelopmental disorders. Am J Hum Genet 94, 415-25 
(2014). 
3. Kong, A. et al. Rate of de novo mutations and the importance of father's age to 
disease risk. Nature 488, 471-5 (2012). 
4. Rahbari, R. et al. Timing, rates and spectra of human germline mutation. Nat Genet 
48, 126-33 (2016). 
5. Wong, W.S. et al. New observations on maternal age effect on germline de novo 
mutations. Nat Commun 7, 10486 (2016). 
6. Samocha, K.E. et al. A framework for the interpretation of de novo variation in 
human disease. Nature Genetics 46, 944-950 (2014). 
7. De Ligt, J. et al. Diagnostic exome sequencing in persons with severe intellectual 
disability. The New England Journal of Medicine 367, 1921-9 (2012). 
8. Iossifov, I. et al. De Novo Gene Disruptions in Children on the Autistic Spectrum. 
Neuron 74, 285-299 (2012). 
9. O’Roak, B.J. et al. Sporadic autism exomes reveal a highly interconnected protein 
network of de novo mutations. Nature 485, 1-7 (2012). 
10. Rauch, A. et al. Range of genetic mutations associated with severe non-syndromic 
sporadic intellectual disability: an exome sequencing study. Lancet 380, 1674-82 
(2012). 
11. Sanders, S.J. et al. De novo mutations revealed by whole-exome sequencing are 
strongly associated with autism. Nature 485, 237-41 (2012). 
12. Zaidi, S. et al. De novo mutations in histone-modifying genes in congenital heart 
disease. Nature 498, 220-3 (2013). 
13. Epi4K Consortium & Epilepsy Phenome/Genome Project. De novo mutations in 
epileptic encephalopathies. Nature 501, 217-21 (2013). 
14. Iossifov, I. et al. The contribution of de novo coding mutations to autism spectrum 
disorder. Nature 515, 216-221 (2014). 
15. EuroEPINOMICS-RES Consortium, Epilepsy Phenome/Genome Project & Epi4K 
Consortium. De novo mutations in synaptic transmission genes including DNM1 
cause epileptic encephalopathies. Am J Hum Genet 95, 360-70 (2014). 
16. De Rubeis, S. et al. Synaptic, transcriptional and chromatin genes disrupted in 
autism. Nature 515, 209-215 (2014). 
17. Fromer, M. et al. De novo mutations in schizophrenia implicate synaptic networks. 
Nature 506, 179-184 (2014). 
18. Gilissen, C. et al. Genome sequencing identifies major causes of severe intellectual 
disability. Nature 511, 344-7 (2014). 
19. Lebrun, N. et al. Early-onset encephalopathy with epilepsy associated with a novel 
splice site mutation in SMC1A. American journal of medical genetics. Part A (2015). 
20. Moore, C. et al. The INTERVAL trial to determine whether intervals between blood 
donations can be safely and acceptably decreased to optimise blood supply: study 
protocol for a randomised controlled trial. Trials 15, 363 (2014). 
21. Akawi, N. et al. Discovery of four recessive developmental disorders using 
probabilistic genotype and phenotype matching among 4,125 families. Nature 
Genetics 47, 1363-1369 (2015). 
22. Meynert, A.M., Ansari, M., FitzPatrick, D.R. & Taylor, M.S. Variant detection 
sensitivity and biases in whole genome and exome sequencing. BMC Bioinformatics 
15, 247 (2014). 
23. Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. bioRxiv 
X, XX-XX (2015). 
24. Springett, A. et al. Congenital Anomaly Statistics 2011: England and Wales. (2013). 
  
Supplementary tables 
 
Table provided in external spreadsheet. 
Supplementary Table 1: Table of de novo mutations in the 4,294 DDD individuals. The table includes 
sex, chromosome, position, reference and alternate alleles, HGNC symbols, VEP consequences, and 
validation status where available. Individual IDs are available on request. This list excludes the sites 
that failed validations, but includes sites that passed validation (confirmed), sites that were 
uncertain (uncertain), and sites that were not tested by secondary validation (NA). Genome 
positions are given as GRCh37 coordinates. 
 
Supplementary Table 2: Proportion of DDD cohort with phenotypic terms that relate to the disorders 
included in the external cohorts in the meta-analyses. 
Disorder Root terms Proportion 
Autism spectrum disorder HP:0000729 0.114 
Congenital heart disorder HP:0002564 0.106 
Intellectual disability HP:0001249,HP:0012443,HP:0100543 0.817 
Schizophrenia HP:0100753 0.000 
Seizures HP:0001250 0.199 
 
 
  
Supplementary Table 3: Details of cohorts used in meta-analyses. This includes numbers of individuals by sex and publication details. 
Phenotype Year Male Female Note Citation 
Intellectual disability 2012 47 53  De Ligt, et al. 
7 
Autism spectrum disorder 2012 314 29 subset of Iossifov, et al. 14 Iossifov, et al. 8 
Autism spectrum disorder 2012 151 58 subset of Iossifov, et al. 8 O’Roak, et al. 9 
Intellectual disability 2012 19 32 
 
Rauch, et al. 10 
Autism spectrum disorder 2012 157 68 subset of Iossifov, et al. 14 Sanders, et al. 11 
Seizures 2013 156 108 
subset of EuroEPINOMICS-RES 
Consortium, et al. 15 
Epi4K Consortium and Epilepsy 
Phenome/Genome Project 13 
Congenital heart disease 2013 220 142 
 
Zaidi, et al. 12 
Seizures 2014 54 38 
 
EuroEPINOMICS-RES 
Consortium, et al. 15 
Schizophrenia 2014 308 317 
 
Fromer, et al. 17 
Intellectual disability 2014 0 0 subset of De Ligt, et al. 7 Gilissen, et al. 18 
Autism spectrum disorder (normal IQ) 2014 1099 74 
Counts are for individuals with IQ >= 
70. 
Iossifov, et al. 14 
Autism spectrum disorder 2014 446 112 Probands with IQ < 70. Iossifov, et al. 14 
Autism spectrum disorder 2014 1192 253 
Counts are extrapolated from the sex 
ratio of individuals with de novos. 
De Rubeis, et al. 16 
 
 
  
Table provided in external spreadsheet. 
Supplementary Table 4: Genes with genome-wide significant statistical evidence to be developmental 
disorder genes. The numbers of unrelated individuals with independent de novo mutations are given for 
protein truncating variants (PTV) and missense variants. If any additional individuals were in other 
cohorts, that number is given in brackets. The P-value reported is the minimum P-value from the testing 
of the DDD dataset or the meta-analysis dataset. The subset providing the P-value is also listed. 
Mutations are considered clustered if the P-value proximity clustering of de novo mutations is less than 
0.01. 
 
 
Supplementary Table 5: Counts of individuals from phenotypes used for meta-analysis, including counts 
of individuals with likely pathogenic de novo mutations in known dominant developmental disorder 
genes. n, number of individuals. 
Disorder Individuals (n) With likely pathogenic (n) 
DDD trios 4294 1136 
Autism spectrum disorder 2780 226 
Seizures 356 57 
Intellectual disability 151 49 
 
 
 
  
Supplementary figures 
 
 
Supplementary Figure 1: Proportion of individuals with a de novo mutation (DNM) likely to be 
pathogenic. These only included individuals with protein altering or protein truncating DNMs in 
dominant or X-linked dominant developmental disorder (DD) associated genes, or males with DNMs in 
hemizygous DD-associated genes. The proportions given are for those individuals with any DNMs rather 
than the total number of individuals in each subset. 
  
 
 
 
Supplementary Figure 2: Phenotypic summaries of genes exceeding genome-wide significance. Each 
gene subfigure has up to three parts. The first part summarises the anthropometric and developmental 
milestones from individuals with de novo mutations (DNMs) in the gene. The second part summarises 
the key Human Phenotype Ontology (HPO) terms for each gene. The HPO terms in the individuals were 
selected, including the ancestral terms. Terms that are rarer in the 4,294 individuals rank higher, 
adjusted by the number of individuals with DNMs who had the term. The heatmaps are shaded by the 
number of individuals with each term. The heatmaps exclude terms that rank lower than a descendant 
term (excluding more general terms if a more specific term occurred first), and terms where fewer than 
25% of individuals had the term, or in genes with less than 8 individuals, terms with fewer than two 
individuals. The third part summarises the facial photographs from individuals with DNMs in each gene. 
The averaged face images are only available for selected genes, based on the availability of sufficient 
high-quality facial photographs of individuals for each gene. 
  
 
 
 
Supplementary Figure 3: Dispersion of de novo mutations and domains for each novel gene. A) CDK13, 
B) CHD4, C) CNOT3, D) CSNK2A1, E) GNAI1, F) KCNQ3, G) MSL3, H) PPM1D, I) PUF60, J) QRICH1, K) SET, L) 
SUV420H1, M) TCF20 and N) ZBTB18. 
  
 
 
 
 
Supplementary Figure 4: Effect of clustering by phenotype on the ability to identify genomewide 
significant genes. A) Comparison of P-values derived from genotypic information alone versus P-values 
that incorporate genotypic information and phenotypic similarity. B) Comparison of P-values from tests 
in the complete DDD cohort versus tests in the subset with seizures. Genes that were previously linked 
to seizures are shaded blue. 
  
  
Supplementary Figure 5: Simulated estimates of power to detect loss-of-function genes in the genome 
at difference cohort sizes, given fixed budgets. 
  
  
Supplementary Figure 6: Neurodevelopmental genes classified by clinical recognisability were compared 
for the gene-wise significance versus the expected number of mutations per gene. Points are shaded by 
recognisability category. Genes have neen separated into two plots, one plot with genes for cryptic 
disorders with low, mild or moderate clinical recognisability, and one plot with genes for distinctive 
disorders with high clinical recognisability. 
 
 
